Open label trial for efficacy and safety of Hydroxychloroquine for systemic lupus erythematosus

Open label trial for efficacy and safety of Hydroxychloroquine for systemic lupus erythematosus - Hydroxychloroquine for systemic lupus erythematosus

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012478

Enrollment

Registered

2014-01-01

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

systemic lupus erythematosus cutaneous lupus erythematosus

Interventions

Treatment with Hydroxychloroquine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with SLE or CLE Patients without retinopathy examined by ophthalmologist.

Exclusion criteria

Exclusion criteria: Patients with severe insufficiency in liver, kidney, heart, bone marrow function. Patients with current or previous history of retinopathy. Patients allergic to 4-aminoquinoline. Other patients who were judged to be ineligible for the study by an attending physician.

Design outcomes

Primary

Measure	Time frame
CLASI score	—

Countries

Japan

Contacts

Public ContactHajime Kono

Department of Internal Medicine, Teikyo University School of Medicine Rheumatology and Allergy

kono@med.teikyo-u.ac.jp03-3964-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026